Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå Àü¸Á(-2030³â) : Áö¿ªº° ºÐ¼® - ±Ë¾ç À¯Çüº°, Ä¡·á À¯Çüº°, °¨¿° ÁßÁõµµº°, ÃÖÁ¾ »ç¿ëÀÚº°
South & Central America Diabetic Foot Ulcer Market Forecast to 2030 - Regional Analysis - By Ulcer Type, Treatment Type, Infection Severity, and End User
»óǰÄÚµå : 1463704
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 109 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,730,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,101,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,472,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº 2022³â 3¾ï 5,691¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2030³â¿¡´Â 5¾ï 4,939¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â°£ ¿¬Æò±Õ 5.5% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»óó °ü¸®¿¡¼­ 3D ÇÁ¸°ÆÃ Ȱ¿ëÀ¸·Î Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀå Ȱ¼ºÈ­

´ç´¢º´ ¹× Ç÷°ü ÁúȯÀ¸·Î ÀÎÇÑ ´Ù¾çÇÑ ÀûÀÀÁõÀ¸·Î ÀÎÇÑ ÇǺΠÁ¶Á÷ ¼Õ»óÀº ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ºÎ´ãÀ» ÁÖ¸ç, 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃÀº ·¹ÀÌ¾î ±â¹Ý ÇÕ¼ºÀ» ±â¹ÝÀ¸·ÎÇϸç, »õ·Î »ý¼º µÈ ¼¼Æ÷ ¹× ¼¼Æ÷ ±â¹Ý Àç·á´Â ¿ø·¡ Á¶Á÷À» ¸ð¹æÇϱâ À§ÇØ ¹èÆ÷ ÇÒ ¼ö ÀÖ½À´Ï´Ù. À§ÇØ ºÐ¹èµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ÀÌÁ¦ ¸· ½ÃÀ۵ǾúÁö¸¸ 3D ÇÁ¸°ÆÃÀº »óó Ä¡·á »ê¾÷¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ ÁøÇÇ Àç»ýÀ» À§ÇÑ Ç÷°ü ½Å»ýÀ» ÃËÁøÇÏ´Â À̿ ¹æÃâ »ýü Àç·á¸¦ Æ÷ÇÔÇÑ ½ÅÁ¦Ç° °³¹ß¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃÀº Ç¥ÁØ ±â¼ú·Î´Â Ä¡À¯Çϱ⠾î·Á¿î Å« »óóÀÇ ÀÀ±Þ óġ¿¡µµ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±Ë¾ç ¹× »óó Ä¡·á¿¡ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼úÀ» »ç¿ëÇÏ´Â °ÍÀº ÇâÈÄ ¸î ³âµ¿¾È ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå¿¡¼­ µÎµå·¯Áø Æ®·»µå·Î ºÎ»óÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå °³¿ä

Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº 2022-2030³â°£ ¿¬Æò±Õ 5.5%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ´ç´¢º´ ¹× °ü·Ã ¸¸¼º »óóÀÇ À¯º´·ü Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡ÀÔ´Ï´Ù. ±×·¯³ª °íµµÀÇ »óó Ä¡·á´Â ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

IDF Diabetes Atlas¿¡ µû¸£¸é 2021³â Áß³²¹ÌÀÇ ´ç´¢º´ ÁöÃâÀº 650¾ï ´Þ·¯¿¡ ´ÞÇϰí 2030³â¿¡´Â 800¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼­ ÀÌ Áö¿ªÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ´ç´¢º´ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ±Ã±ØÀûÀ¸·Î »óó °ü¸® Á¦Ç°ÀÇ »ç¿ëÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ÀϺΠ½ÃÀå ÁøÃâ±â¾÷µéÀº ÀÓ»óÀǵéÀÌ ÀÓ»ó Áö½ÄÀ» Çâ»ó½ÃŰ°í ´ç´¢º´¼º Á·ºÎ ±Ë¾ç°ú °°Àº ¸¸¼º »óóÀÇ Ä¡·á ¿É¼ÇÀ» ÀÌÇØÇÒ ¼ö ÀÖµµ·Ï ±³À° ¹× ÈÆ·Ã °úÁ¤À» ½Ç½ÃÇϰí ÀÖÀ¸¸ç, 2021³â 4¿ù MedlineÀº ´ç´¢º´¼º Á·ºÎ ±Ë¾ç¿¡ ´ëÇÑ °í±Þ Ä¡·á ¿É¼ÇÀ» °¡Áø ÀÓ»óÀǸ¦ ¾ç¼ºÇϱâ À§ÇØ, ¾Æ¸£ÇîÆ¼³ª¿¡¼­ »õ·Î¿î ¸¸¼º »óó °ü¸® °úÁ¤ ½Ã¸®Á ½ÃÀÛÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¾Æ¸£ÇîÆ¼³ª ½ÃÀå ¼ºÀå¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå ¼¼ºÐÈ­

Ä¡·á À¯Çü¿¡ µû¶ó Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº °í±Þ »óó Ä¡·á µå·¹½Ì, Ä¡·á Àåºñ, »ý¹°ÇÐÀû Á¦Á¦·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â °í±Þ »óó Ä¡·á µå·¹½Ì ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±Ë¾ç À¯Çü¿¡ µû¶ó Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº ½Å°æÇãÇ÷¼º ±Ë¾ç, ½Å°æº´¼º ±Ë¾ç, ÇãÇ÷¼º ±Ë¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ½Å°æÇãÇ÷¼º ±Ë¾ç ºÎ¹®Àº 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

°¨¿°ÀÇ ÁßÁõµµ¿¡ µû¶ó Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº °æÁõ, Áߵ, ÁßÁõÀ¸·Î ±¸ºÐµË´Ï´Ù. °æÁõ ºÎ¹®ÀÌ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î Áß³²¹Ì ´ç´¢º´¼º Á·ºÎ ±Ë¾ç ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÀçÅÃÄ¡·á·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì·Î ±¸ºÐµÇ¸ç, 2022³â Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀåÀº ºê¶óÁúÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.

Convatec Group Plc, 3M Co, Coloplast AS, Smith &Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc, Molnlycke Health Care AB, MiMedx Group Inc´Â Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ¼±µµÀûÀÎ ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå ±¸µµ

Á¦5Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦6Àå ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®

Á¦7Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - ¸ÅÃâ°ú ¿¹Ãø(-2030³â) : Ä¡·á À¯Çüº°

Á¦8Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - ¸ÅÃâ°ú ¿¹Ãø(-2030³â) : ±Ë¾ç À¯Çüº°

Á¦9Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - ¸ÅÃâ°ú ¿¹Ãø(-2030³â) : °¨¿° ÁßÁõµµº°

Á¦10Àå Áß³²¹ÌÀÇ ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - ¸ÅÃâ°ú ¿¹Ãø(-2030³â) : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - Áß³²¹Ì ½ÃÀå ºÐ¼®

Á¦12Àå ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå ¾÷°è »óȲ

Á¦13Àå ´ç´¢º´¼º Á·±Ë¾ç ½ÃÀå - ÁÖ¿ä ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The South & Central America diabetic foot ulcer market was valued at US$ 356.91 million in 2022 and is expected to reach US$ 549.39 million by 2030; it is estimated to grow at a CAGR of 5.5% from 2022 to 2030.

Use of 3D Printing in Wound Care Management Fuels the South & Central America Diabetic Foot Ulcer Market

Skin tissue damage caused by various indications due to diabetes and vascular diseases significantly burdens the healthcare systems. 3D bioprinting is based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still nascent, 3D printing can potentially revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that promote angiogenesis for dermal regeneration. In addition, 3D bioprinting helps patch large wounds that are hard to heal with standard techniques. The use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the diabetic foot ulcer market in the coming years.

South & Central America Diabetic Foot Ulcer Market Overview

The South & Central America diabetic foot ulcer market is estimated to grow at a CAGR of 5.5% from 2022 to 2030. Key factors driving the market growth are increasing prevalence of diabetes and related chronic wounds and the rise in geriatric population propel market growth. However, high cost of advanced wound care treatments hinders the market growth.

According to IDF Diabetes Atlas, in 2021, diabetes accounted for US$ 65 billion in expenditure in South & Central America, which is estimated to reach US$ 80 billion by 2030. Thus, the increasing healthcare spending and the rising prevalence of diabetes in the region are factors expected to boost market growth, ultimately increasing wound care product use. Additionally, several market players are implementing awareness and training courses to empower clinicians to enhance clinical knowledge and understand treatment options for chronic wounds such as diabetic foot ulcers. In April 2021, Medline launched a new series of chronic wound care courses in Argentina to train clinicians with advanced treatment options for diabetic foot ulcers. Such initiatives will support the market growth in Argentina.

South & Central America Diabetic Foot Ulcer Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Diabetic Foot Ulcer Market Segmentation

Based on treatment type, the South & Central America diabetic foot ulcer market is segmented into advanced wound care dressings, therapy device, and biologics. The advanced wound care dressings segment held largest share in 2022.

Based on ulcer type, the South & Central America diabetic foot ulcer market is segmented into neuro-lschemic ulcers, neuropathic ulcers, and ischemic ulcers. The neuro-lschemic ulcers segment held largest share in 2022.

Based on infection severity, the South & Central America diabetic foot ulcer market is segmented into mild, moderate, and severe. The mild segment held largest share in 2022.

Based on end user, the South & Central America diabetic foot ulcer market is segmented into hospitals, ambulatory surgical centers, and home care. The hospitals segment held largest share in 2022.

Based on country, the South & Central America diabetic foot ulcer market is segmented into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America diabetic foot ulcer market in 2022.

Convatec Group Plc, 3M Co, Coloplast AS, Smith & Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc., Molnlycke Health Care AB, and MiMedx Group Inc are some of the leading companies operating in the South & Central America diabetic foot ulcer market.

Table Of Contents

Table of Content

1. Introduction

2. Executive Summary

3. Research Methodology

4. South & Central America Diabetic Foot Ulcer Market Landscape

5. South & Central America Diabetic Foot Ulcer Market - Key Industry Dynamics

6. Diabetic Foot Ulcer Market - South & Central America Market Analysis

7. South & Central America Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - by Treatment Type

8. South & Central America Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Ulcer Type

9. South & Central America Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By Infection Severity

10. South & Central America Diabetic Foot Ulcer Market - Revenue and Forecast to 2030 - By End User

11. Diabetic Foot Ulcer Market - South & Central America Market Analysis

12. Diabetic Foot Ulcer Market Industry Landscape

13. Diabetic Foot Ulcer Market - Key Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â